Analyst views clinical results as central to Bavarian Nordic's external financing
Danish senior analyst Søren Løntoft Hansen views phase I/II results to be key in Bavarian Nordic's efforts to attain external financing.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
The Danish bank Sydbank sees positive aspects to Bavarian Nordic's Monday announcement that it has received a positive batch of data on the vaccine candidate ABNCovid2 against Covid-19 and will soon commence in-human studies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
.jpg&w=384&q=75)
